Freedom Capital Markets Downgrades AtriCure to Hold, Raises Price Target to $57

Benzinga Newsdesk www.benzinga.com Negative 59.8%

Neg 59.8% Neu 0% Pos 0%

Freedom Capital Markets analyst Keith Hinton downgrades AtriCure (NASDAQ:ATRC) from Buy to Hold and raises the price target from $43 to $57.